Literature DB >> 26319548

Bayesian population modeling of drug dosing adherence.

Kelly Fellows1,2, Colin J Stoneking2, Murali Ramanathan3.   

Abstract

Adherence is a frequent contributing factor to variations in drug concentrations and efficacy. The purpose of this work was to develop an integrated population model to describe variation in adherence, dose-timing deviations, overdosing and persistence to dosing regimens. The hybrid Markov chain-von Mises method for modeling adherence in individual subjects was extended to the population setting using a Bayesian approach. Four integrated population models for overall adherence, the two-state Markov chain transition parameters, dose-timing deviations, overdosing and persistence were formulated and critically compared. The Markov chain-Monte Carlo algorithm was used for identifying distribution parameters and for simulations. The model was challenged with medication event monitoring system data for 207 hypertension patients. The four Bayesian models demonstrated good mixing and convergence characteristics. The distributions of adherence, dose-timing deviations, overdosing and persistence were markedly non-normal and diverse. The models varied in complexity and the method used to incorporate inter-dependence with the preceding dose in the two-state Markov chain. The model that incorporated a cooperativity term for inter-dependence and a hyperbolic parameterization of the transition matrix probabilities was identified as the preferred model over the alternatives. The simulated probability densities from the model satisfactorily fit the observed probability distributions of adherence, dose-timing deviations, overdosing and persistence parameters in the sample patients. The model also adequately described the median and observed quartiles for these parameters. The Bayesian model for adherence provides a parsimonious, yet integrated, description of adherence in populations. It may find potential applications in clinical trial simulations and pharmacokinetic-pharmacodynamic modeling.

Entities:  

Keywords:  Adherence; Circular distribution; Compliance; Dosing patterns; Runs

Mesh:

Year:  2015        PMID: 26319548     DOI: 10.1007/s10928-015-9439-8

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  14 in total

1.  Developing compliance instructions for drug labeling.

Authors:  G Levy; M K Zamacona; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  2000-12       Impact factor: 6.875

2.  Comparing hierarchical models for spatio-temporally misaligned data using the deviance information criterion.

Authors:  L Zhu; B P Carlin
Journal:  Stat Med       Date:  2000 Sep 15-30       Impact factor: 2.373

Review 3.  Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories.

Authors:  Terrence F Blaschke; Lars Osterberg; Bernard Vrijens; John Urquhart
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-09-19       Impact factor: 13.820

4.  Penalized loss functions for Bayesian model comparison.

Authors:  Martyn Plummer
Journal:  Biostatistics       Date:  2008-01-21       Impact factor: 5.899

Review 5.  A pharmacokinetic perspective on medicament noncompliance.

Authors:  G Levy
Journal:  Clin Pharmacol Ther       Date:  1993-09       Impact factor: 6.875

6.  Prediction of diltiazem plasma concentration curves from limited measurements using compliance data.

Authors:  A Rubio; C Cox; M Weintraub
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  A hybrid Markov chain-von Mises density model for the drug-dosing interval and drug holiday distributions.

Authors:  Kelly Fellows; Vivian Rodriguez-Cruz; Jenna Covelli; Alyssa Droopad; Sheril Alexander; Murali Ramanathan
Journal:  AAPS J       Date:  2015-01-22       Impact factor: 4.009

8.  Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.

Authors:  R M Savic; A Barrail-Tran; X Duval; G Nembot; X Panhard; D Descamps; C Verstuyft; B Vrijens; A-M Taburet; C Goujard; F Mentré
Journal:  Clin Pharmacol Ther       Date:  2012-10-03       Impact factor: 6.875

9.  Electronic monitoring of variation in drug intakes can reduce bias and improve precision in pharmacokinetic/pharmacodynamic population studies.

Authors:  Bernard Vrijens; Els Goetghebeur
Journal:  Stat Med       Date:  2004-02-28       Impact factor: 2.373

10.  A Markov mixed effect regression model for drug compliance.

Authors:  P Girard; T F Blaschke; H Kastrissios; L B Sheiner
Journal:  Stat Med       Date:  1998-10-30       Impact factor: 2.373

View more
  1 in total

1.  Perspectives on the history and scientific contributions of Gerhard Levy.

Authors:  Ho-Leung Fung; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-24       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.